Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

9 evidence topics · 14 sources

Summary: anticipated place in therapy

Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.

Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.

The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.

Guideline sequencing: early advanced therapy and absence of a hierarchy